NAS:TRIB (Ireland)
Business Description
Trinity Biotech PLC
NAICS : 325413
SIC : 2835
IDA Business Park, Bray, Co. Wicklow, Dublin, IRL
Description
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Ireland of which it derives a majority of its revenues from the Americas segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | -0.06 | |||||
| Debt-to-Equity | -12.17 | |||||
| Debt-to-EBITDA | 23.14 | |||||
| Interest Coverage | 1.64 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.68 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.15 | |||||
| 9-Day RSI | 58.71 | |||||
| 14-Day RSI | 57.01 | |||||
| 6-1 Month Momentum % | 20.8 | |||||
| 12-1 Month Momentum % | -39.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.66 | |||||
| Quick Ratio | 1.8 | |||||
| Cash Ratio | 0.63 | |||||
| Days Inventory | 230.31 | |||||
| Days Sales Outstanding | 65.44 | |||||
| Days Payable | 131.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.97 | |||||
| Operating Margin % | 12.37 | |||||
| Net Margin % | -15.1 | |||||
| ROA % | -10.69 | |||||
| ROIC % | 8.54 | |||||
| ROC (Joel Greenblatt) % | 9.69 | |||||
| ROCE % | 6.56 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 7.01 | |||||
| PS Ratio | 0.44 | |||||
| Price-to-Operating-Cash-Flow | 14.98 | |||||
| EV-to-EBIT | 36.35 | |||||
| EV-to-EBITDA | 36.35 | |||||
| EV-to-Revenue | 1.41 | |||||
| EV-to-FCF | -21.62 | |||||
| Price-to-Median-PS-Value | 0.26 | |||||
| Earnings Yield (Greenblatt) % | 2.76 | |||||
| Forward Rate of Return (Yacktman) % | -45.38 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:TRIB
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 86.147 | ||
| EPS (TTM) ($) | -0.545 | ||
| Beta | 1.28 | ||
| Volatility % | 52.97 | ||
| 14-Day RSI | 57.01 | ||
| 14-Day ATR ($) | 0.082297 | ||
| 20-Day SMA ($) | 1.356635 | ||
| 12-1 Month Momentum % | -39.87 | ||
| 52-Week Range ($) | 0.86 - 3.05 | ||
| Shares Outstanding (Mil) | 38.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Trinity Biotech PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||